Medical Innovation Exchange

Daiichi Sankyo’s survival data means it may finally be ready to compete with Novartis’, Astellas’ marketed AML meds


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.